Precision Medicine

Beyond the headlines of EHA 2026, Eli Lilly's latest data and acquisitions reveal a bold strategy to conquer the hematology market. It's a three-pronged assault.

Quoin Pharmaceuticals files the first-ever drug application for Peeling Skin Syndrome, offering a glimmer of hope for patients with no treatment options.

Inipharm's INI-822 study leverages genetic insights for an oral MASH therapy, challenging injectable rivals and offering new hope for high-risk patients.

A new study reveals molecular and AI-imaging tests provide distinct clues for Parkinson's, championing a dual-biomarker approach for earlier, more accurate diagnosis.

Origin Agritech's gene-editing breakthrough allows corn to mature faster without sacrificing yield, a holy grail for breeders and a boon for global food security.

A new alliance between Solid Biosciences and NanoMosaic pairs advanced delivery with precision analytics, aiming to de-risk development and redefine success.

Early data shows a first-in-class oral drug helps immunotherapy work again in resistant tumors, offering a glimpse of hope where options are running out.

An innovator in single-molecule imaging is teaming up with a multiplex giant. This collaboration could redefine diagnostic sensitivity and market dynamics.

Ohio-based Xact Labs secures a key patent for technology that integrates genetic data into pharmacies, aiming to make prescriptions safer and more effective.

Researchers have discovered a metabolic 'Achilles' heel' in a rare liver cancer, offering a new treatment path beyond ineffective chemotherapy.

Endeavor Health's new genetic test provides a "floodlight" on heart disease risk, but with no insurance coverage, who will get to see the light?

Early Phase 1 data for APR-1051 reveals anti-tumor activity and manageable safety, offering a new glimmer of hope for patients with advanced solid tumors.

A single blood test can now simultaneously track immune response, tumor changes, and resistance, offering new hope for personalizing sarcoma immunotherapy.

A Shanghai medical center pioneers a gallbladder-preserving surgery, promising a life without post-op pain. But does the science support a global revolution?

Gene Solutions' SPOT-MAS 10 test gains FDA Breakthrough Designation, accelerating its path to the U.S. market and heralding a new era in early cancer detection.

Celebrating two decades of innovation, RadioMedix unveils promising new alpha therapy data for pancreatic cancer at the SNMMI 2026 annual meeting.

Uncommon Productions' 'Cracking the Code' earns top honors, celebrating the biotech revolution and the power of scientific ingenuity.

Groundbreaking research on new drug classes, the gut-brain axis, and personalized medicine will be unveiled at the upcoming American Headache Society meeting.

Therini Bio's novel drug THN391 enters trials, targeting inflammation in diabetic eye disease, while a next-gen combo therapy aims to redefine care.

A new partnership between biotech leader Debut and Amazonian expert Natura aims to revolutionize anti-aging skincare with AI-discovered ingredients.